These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 18485453)

  • 1. Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran.
    Agnelli G; Eriksson BI; Cohen AT; Bergqvist D; Dahl OE; Lassen MR; Mouret P; Rosencher N; Andersson M; Bylock A; Jensen E; Boberg B;
    Thromb Res; 2009; 123(3):488-97. PubMed ID: 18485453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
    Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
    Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran.
    Harenberg J; Jörg I; Weiss C
    Int J Toxicol; 2006; 25(3):165-9. PubMed ID: 16717032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.
    Eriksson BI; Agnelli G; Cohen AT; Dahl OE; Mouret P; Rosencher N; Eskilson C; Nylander I; Frison L; Ogren M;
    Thromb Haemost; 2003 Feb; 89(2):288-96. PubMed ID: 12574809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ximelagatran for treatment and prophylaxis of recurrent events in deep vein thrombosis.
    Koscielny J; Kiesewetter H; Jörg I; Harenberg J
    Clin Appl Thromb Hemost; 2007 Jul; 13(3):299-307. PubMed ID: 17636192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.
    Schulman S; Wåhlander K; Lundström T; Clason SB; Eriksson H;
    N Engl J Med; 2003 Oct; 349(18):1713-21. PubMed ID: 14585939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.
    Francis CW; Berkowitz SD; Comp PC; Lieberman JR; Ginsberg JS; Paiement G; Peters GR; Roth AW; McElhattan J; Colwell CW;
    N Engl J Med; 2003 Oct; 349(18):1703-12. PubMed ID: 14585938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melagatran and ximelagatran: new drug. No real simplification of anticoagulant therapy.
    Prescrire Int; 2005 Aug; 14(78):127-32. PubMed ID: 16106594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ximelagatran: a new type of oral anticoagulant.
    Kwok L; Molckovsky D; Boucher M
    Int J Technol Assess Health Care; 2005; 21(4):480-6. PubMed ID: 16262971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement.
    Eriksson BI; Borris L; Dahl OE; Haas S; Huisman MV; Kakkar AK; Misselwitz F; Kälebo P;
    J Thromb Haemost; 2006 Jan; 4(1):121-8. PubMed ID: 16409461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.
    Fiessinger JN; Huisman MV; Davidson BL; Bounameaux H; Francis CW; Eriksson H; Lundström T; Berkowitz SD; Nyström P; Thorsén M; Ginsberg JS;
    JAMA; 2005 Feb; 293(6):681-9. PubMed ID: 15701909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran.
    Harenberg J; Ingrid J; Tivadar F
    Isr Med Assoc J; 2002 Nov; 4(11):1003-5. PubMed ID: 12489490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial.
    Tangelder MJ; Frison L; Weaver D; Wilcox RG; Bylock A; Emanuelsson H; Held P; Oldgren J
    Am Heart J; 2008 Feb; 155(2):382-7. PubMed ID: 18215612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
    Douketis JD; Arneklev K; Goldhaber SZ; Spandorfer J; Halperin F; Horrow J
    Arch Intern Med; 2006 Apr; 166(8):853-9. PubMed ID: 16636210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran.
    Eriksson H; Lundström T; Wåhlander K; Clason SB; Schulman S;
    Thromb Haemost; 2005 Sep; 94(3):522-7. PubMed ID: 16268466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the oral direct thrombin inhibitor ximelagatran: not yet the end of the warfarin era..
    Mohapatra R; Tran M; Gore JM; Spencer FA
    Am Heart J; 2005 Jul; 150(1):19-26. PubMed ID: 16084146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of bleeding after concomitant administration of antiplatelet and anticoagulant agents in lower limb arthroplasty.
    Dahl OE; Ogren M; Agnelli G; Eriksson BI; Cohen AT; Mouret P; Rosencher N; Bylock A; Panfilov S; Andersson M
    Pathophysiol Haemost Thromb; 2006; 35(6):428-34. PubMed ID: 17565235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study.
    Heit JA; Colwell CW; Francis CW; Ginsberg JS; Berkowitz SD; Whipple J; Peters G;
    Arch Intern Med; 2001 Oct; 161(18):2215-21. PubMed ID: 11575978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma.
    Boström SL; Hansson GF; Sarich TC; Wolzt M
    Thromb Res; 2004; 113(1):85-91. PubMed ID: 15081569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.